{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T03:40:30Z","timestamp":1719718830537},"reference-count":10,"publisher":"Medical Association of Nippon Medical School","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nippon Med Sch"],"published-print":{"date-parts":[[2017]]},"DOI":"10.1272\/jnms.84.291","type":"journal-article","created":{"date-parts":[[2017,12,26]],"date-time":"2017-12-26T22:18:21Z","timestamp":1514326701000},"page":"291-293","source":"Crossref","is-referenced-by-count":5,"title":["A Drug Interaction between Crizotinib and Warfarin in Non-Small-Cell Lung Cancer: A Case Report"],"prefix":"10.1272","volume":"84","author":[{"given":"Yu","family":"Kubomura","sequence":"first","affiliation":[{"name":"Section of Pharmaceutical Services, Nippon Medical School Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Ise","sequence":"additional","affiliation":[{"name":"Section of Pharmaceutical Services, Nippon Medical School Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Wako","sequence":"additional","affiliation":[{"name":"Section of Pharmaceutical Services, Nippon Medical School Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirou","family":"Katayama","sequence":"additional","affiliation":[{"name":"Section of Pharmaceutical Services, Nippon Medical School Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rintaro","family":"Noro","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Kubota","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"21","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Wang C, Abe S, Matsuda K, Yu C, Li Y, Usuki J, Azuma A, Kudoh S: Effects of gefitinib on radiation-induced lung injury in mice. J Nippon Med Sch 2008; 75: 96-105.","DOI":"10.1272\/jnms.75.96"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Li C, Gemma A, Minegishi Y, Matsuda K, Seike Y, Noro R, Shionoya A, Kawakami A, Ogawa N, Kudoh S: In vitro simulation study of individualized chemotherapy in lung cancer. J Nippon Med Sch 2007; 74: 217-222.","DOI":"10.1272\/jnms.74.217"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Timm A, Kolesar JM: Crizotinib for the treatment of non-small-cell lung cancer. Am J Health Syst Pharm 2013; 70: 943-947.","DOI":"10.2146\/ajhp120261"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Segal EM, Flood MR, Mancini RS, Whiteman RT, Friedt GA, Kramer AR, Hofstetter MA: Oral Chemotherapy Food and Drug Interactions: A Comprehensive Review of the Literature. J Oncol Prac 2014; 10: e255-e268.","DOI":"10.1200\/JOP.2013.001183"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Cropp JS, Bussey HI: A review of enzyme induction of warfarin metabolism with recommendations for patient management. Pharmacotherapy 1997; 17: 917-928.","DOI":"10.1002\/j.1875-9114.1997.tb03782.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Ferrari M, Pengo V, Barolo M, Bezzo F, Padrini R: Assessing the relative potency of (S)- and (R)-warfarin with a new PK-PD model, in relation to VKORC1 genotypes. Eur J Clin Pharmacol 2017; 73: 699-707.","DOI":"10.1007\/s00228-017-2248-9"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Onoda S, Mitsufuji H, Yanase N, Ryuge N, Kato E, Wada M, Ishii K, Hagiri S, Yamamoto M, Yokoba M, Yanaihara T, Kuboto M, Takada N, Katagiri M, Abe T, Tanaka N, Kobayashi H, Masuda N: Drug Interaction Between Gefitinib and Warfarin. Jpn J Clin Oncol 2005; 35: 478-482.","DOI":"10.1093\/jjco\/hyi122"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Foxx-Lupo WT, Sing S, Alwan L, Tykodi SS: A Drug Interaction Between Cabozantinib and Warfarin in a Patient With Renal Cell Carcinoma. Clin Genitourinary Cancer 2016; 14: e119-e121.","DOI":"10.1016\/j.clgc.2015.09.015"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Thomas KS, Billingsley A, Amarshi N, Nair BA: Elevated international normalized ratio associated with concomitant warfarin and erlotinib. Am J Health Syst Pharm 2010; 67: 1426-1429.","DOI":"10.2146\/ajhp090202"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Borkowski AA, Kardani A, Mastorides SM, Thomas LB: Warfarin pharmacogenomics: recommendations with available patented clinical technologies. Recent Pat Biotechnol 2014; 8: 110-115.","DOI":"10.2174\/1872208309666140904112003"}],"container-title":["Journal of Nippon Medical School"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/84\/6\/84_291\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T03:25:43Z","timestamp":1719717943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/84\/6\/84_291\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1272\/jnms.84.291","relation":{},"ISSN":["1345-4676","1347-3409"],"issn-type":[{"value":"1345-4676","type":"print"},{"value":"1347-3409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}